188 related articles for article (PubMed ID: 30032487)
1. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Br J Clin Pharmacol; 2018 Nov; 84(11):2673-2677. PubMed ID: 30032487
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
3. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
[TBL] [Abstract][Full Text] [Related]
4. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.
Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M
Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Saleh MN; Bussel JB; Cheng G; Meyer O; Bailey CK; Arning M; Brainsky A;
Blood; 2013 Jan; 121(3):537-45. PubMed ID: 23169778
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
7. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
8. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
14. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Bussel JB; Saleh MN; Vasey SY; Mayer B; Arning M; Stone NL
Br J Haematol; 2013 Feb; 160(4):538-46. PubMed ID: 23278590
[TBL] [Abstract][Full Text] [Related]
15. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
16. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
[TBL] [Abstract][Full Text] [Related]
17. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
[TBL] [Abstract][Full Text] [Related]
19. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
